IPCALAB

IPCA Laboratories Limited
Mid-capPharma

What the six lenses say about IPCALAB — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1770.4
2026-07-10
VWAP · 1Y anchor
₹1490
+18.8% from VWAP
P/E · TTM
39.4×
TTM EPS ₹45.0
52-week range
96%
position low→high
RSI(14)
70
momentum

Own sector index

Pharma
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How IPCALAB’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
9.0
avg conviction decile
Leadership
1/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD10100

The actual numbers

Price vs VWAP (1y)+18.8%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+16.8%
Price vs 50-EMA+9.0%
RSI(14)70
RS vs Nifty 500 · 3M+18.3%
RS vs sector · 3M+5.8%
52-week range96%
Volume vs 30d avg0.53×
Volume vs 60d avg0.53×
ATR(14) · volatility55.3
Bollinger width · vol contraction0.205
FundamentalD656

The actual numbers

Return on equity (ROE)16.0%
Return on capital (ROCE)17.3%
Operating margin17.1%
Net margin12.3%
Revenue growth · YoY+7.9%
EPS growth · YoY+54.7%
Debt / equity0.10×

Full 8-quarter history in the financials table below.

ValuationD417

The actual numbers

P/E (TTM)39.4×
TTM EPS₹45.0
52-week range96%
CatalystD121

The actual numbers

Earnings & momentum17
Capital actions11
Governance54

Every filing in the corporate-announcements panel below.

FlowD858

The actual numbers

Promoter holding44.7%
Delivery · 30d avg51.3%
Up/down-day asymmetry6.4pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D8 ) ÷ 2 = 9.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
96
Conviction score 96/100 · avg-decile strength 9.0/10

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.1pp
+3.8pp
+5.4pp
+21.9pp
+19.1pp
+28.1pp
Nifty 500
Broad-market baseline
-0.3pp
+3.8pp
+4.8pp
+18.3pp
+14.1pp
+24.2pp
Sector
Own-sector index
+2.4pp
+5.8pp
-0.3pp
+6.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

IPCALAB daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1770.40+8.00

Relative strength

RS vs baseline · rebased to 100

IPCALAB ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
143.73-0.43

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)2,0932,3552,2452,2472,3092,5562,3922,388
↳ change QoQ+12.5%-4.7%+0.1%+2.8%+10.7%-6.4%-0.2%
EBITDA (₹cr)413468483429416545533484
EBITDA margin19.8%19.9%21.5%19.1%18.0%21.3%22.3%20.3%
PAT (₹cr)19924627664233281364307
↳ change QoQ+23.4%+12.5%-76.8%+264.1%+20.6%+29.5%-15.7%
Net margin9.5%10.4%12.3%2.9%10.1%11.0%15.2%12.9%
EPS (₹)7.589.059.782.679.1911.1412.8611.79
D/E
YoY growth · Mar '26Revenue +6.3% YoYPAT +379.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 12 Jun '26
    MEDIUMcapital
    Press Release

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jun '26
    LOWgovernance
    Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMcapital
    Dividend

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMgovernance
    Appointment

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    HIGHearnings
    Outcome of Board Meeting

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 21 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Apr '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Feb '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 16 Feb '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Feb '26
    HIGHearnings
    Outcome of Board Meeting

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 9 Feb '26
    LOWgovernance
    General Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Feb '26
    LOWgovernance
    General Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Feb '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds IPCALAB

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma